Insider · CIK 0001848718
Ryan Edward Brown
Files at SRPT (Sarepta Therapeutics, Inc.). First filing Mar 5, 2024, latest Jun 25, 2024.
In brief
Ryan Edward Brown files SEC Form 4 as officer at SRPT (Sarepta Therapeutics, Inc.). Since Mar 5, 2024, Ryan Edward Brown has reported 0 open-market buys worth $0 and 2 open-market sells worth $6.5M, the latest filed on Jun 25, 2024.
A track record needs three past buys with six months of prices behind them; Ryan Edward Brown has 0, so none is measured yet.
The newest scored trade: sold $6.3M of SRPT on Jun 25, 2024, filed Jun 25, 2024, scored 33 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SRPT: Sarepta Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Sarepta Therapeutics, Inc. | $6.3M 38,957 shares | -69% | +135% from low-4% from high | |
| 43Moderate | Sarepta Therapeutics, Inc. | $251k 2,000 shares | -6% | +91% from low-18% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 25, 2024 | SRPT SAREPTA THERAPEUTICS INC | 38,957 0.04% of outstanding | $6.4M | Jun 25, 2024 | none |
| Mar 1, 2024 | SRPT Sarepta Therapeutics, Inc. | 2,269 0.00% of outstanding | $285k | Mar 1, 2024 | none |
Transactions
Every row this insider has filed, 21 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 21, 2024 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,250 | - | - | 34,938 | Jun 25, 2024 |
| Jun 24, 2024 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock10b5-1 | -2,352 | $164.64 | $387k | 32,586 | Jun 25, 2024 |
| Jun 25, 2024 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +23,500 | $62.77 | $1.5M | 56,086 | Jun 25, 2024 |
| Jun 25, 2024 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,644 | $158.07 | $1.2M | 48,442 | Jun 25, 2024 |
| Jun 25, 2024 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,200 | $159.14 | $350k | 46,242 | Jun 25, 2024 |
| Jun 25, 2024 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -975 | $160.31 | $156k | 45,267 | Jun 25, 2024 |
| Jun 25, 2024 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,168 | $161.82 | $674k | 41,099 | Jun 25, 2024 |
| Jun 25, 2024 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -17,581 | $162.65 | $2.9M | 23,518 | Jun 25, 2024 |
| Jun 25, 2024 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,840 | $163.53 | $628k | 19,678 | Jun 25, 2024 |
| Jun 25, 2024 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,549 | $164.52 | $419k | 17,129 | Jun 25, 2024 |
| Jun 21, 2024 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Performance Stock Unitsderivative10b5-1 | +5,500 | $0.00 | $0 | 5,500 | Jun 25, 2024 |
| Jun 21, 2024 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Performance Stock Unitsderivative10b5-1 | +6,250 | $0.00 | $0 | 6,250 | Jun 25, 2024 |
| Jun 21, 2024 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Performance Stock Unitsderivative10b5-1 | -6,250 | $0.00 | $0 | 0 | Jun 25, 2024 |
| Jun 25, 2024 | SRPT Sarepta Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -23,500 | $0.00 | $0 | 0 | Jun 25, 2024 |
| Mar 7, 2024 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -506 | $120.49 | $61k | 29,587 | Mar 11, 2024 |
| Mar 8, 2024 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -899 | $123.14 | $111k | 28,688 | Mar 11, 2024 |
| Mar 4, 2024 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -1,734 | $125.32 | $217k | 30,093 | Mar 6, 2024 |
| Mar 1, 2024 | SRPT Sarepta Therapeutics, Inc. | FTax withholding Common Stock | -269 | $126.19 | $34k | 27,827 | Mar 5, 2024 |
| Mar 1, 2024 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +6,000 | $0.00 | $0 | 33,827 | Mar 5, 2024 |
| Mar 1, 2024 | SRPT Sarepta Therapeutics, Inc. | SOpen-market sale Common Stock | -2,000 | $125.34 | $251k | 31,827 | Mar 5, 2024 |
| Mar 1, 2024 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | -12,500 | $0.00 | $0 | 12,500 | Mar 5, 2024 |
Questions about Ryan Edward Brown
Answered from the filings on this page, as of the latest one.
Is Ryan Edward Brown buying or selling?
Not in the last 12 months. Ryan Edward Brown's latest open-market trade on SEC Form 4 was sold $6.3M of SRPT on Jun 25, 2024.
How did Ryan Edward Brown's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ryan Edward Brown has 0.
Where does Ryan Edward Brown file Form 4?
Ryan Edward Brown has filed Form 4 at SRPT (Sarepta Therapeutics, Inc.) as EVP, General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.